详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

88| 认领 | 链接全文 |

文献详情

编号/登记号：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究类型：

研究参与人：

研究单位： [1]Shanghai Chest Hospital [2]Shanghai Chest Hospital [3]The Affiliated Cancer Hospital of Chongqing University [4]Zhejiang University [5]Sun Yat-sen University [6]The First Affiliated Hospital of University of Science and Technology of China [7]Sichuan Cancer Hospital and Research Institute [8]Tianjin Cancer Hospital [9]Peking University Cancer Hospital & Institute [10]Wuhan University [11]Jiangsu Cancer Institute & Hospital [12]Hubei Provincial People's Hospital [13]Jiangsu Hansoh Pharmaceutical Co., Ltd.

研究目的：

This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of Almonertinib treatment in patients with EGFR mutation positive and advanced non-small cell lung cancer (NSCLC) who are intolerant to the safety of osimertinib treatment.

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题